Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2.
dc.contributor.author | Denninger, Viola | |
dc.contributor.author | Xu, Catherine K | |
dc.contributor.author | Meisl, Georg | |
dc.contributor.author | Morgunov, Alexey S | |
dc.contributor.author | Fiedler, Sebastian | |
dc.contributor.author | Ilsley, Alison | |
dc.contributor.author | Emmenegger, Marc | |
dc.contributor.author | Malik, Anisa Y | |
dc.contributor.author | Piziorska, Monika A | |
dc.contributor.author | Schneider, Matthias | |
dc.contributor.author | Devenish, Sean RA | |
dc.contributor.author | Kosmoliaptsis, Vasilis | |
dc.contributor.author | Aguzzi, Adriano | |
dc.contributor.author | Fiegler, Heike | |
dc.contributor.author | Knowles, Tuomas | |
dc.date.accessioned | 2022-04-30T01:04:10Z | |
dc.date.available | 2022-04-30T01:04:10Z | |
dc.date.issued | 2022-04-08 | |
dc.identifier.issn | 2373-8227 | |
dc.identifier.other | 35352558 | |
dc.identifier.other | PMC8982494 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/336648 | |
dc.description | Funder: Universit?tsspital Z?rich | |
dc.description | Funder: Biotechnology and Biological Sciences Research Council | |
dc.description | Funder: NOMIS Stiftung | |
dc.description | Funder: Universit?t Z?rich | |
dc.description.abstract | Recent efforts in understanding the course and severity of SARS-CoV-2 infections have highlighted both potentially beneficial and detrimental effects of cross-reactive antibodies derived from memory immunity. Specifically, due to a significant degree of sequence similarity between SARS-CoV-2 and other members of the coronavirus family, memory B-cells that emerged from previous infections with endemic human coronaviruses (HCoVs) could be reactivated upon encountering the newly emerged SARS-CoV-2, thus prompting the production of cross-reactive antibodies. Determining the affinity and concentration of these potentially cross-reactive antibodies to the new SARS-CoV-2 antigens is therefore particularly important when assessing both existing immunity against common HCoVs and adverse effects like antibody-dependent enhancement (ADE) in COVID-19. However, these two fundamental parameters cannot easily be disentangled by surface-based assays like enzyme-linked immunosorbent assays (ELISAs), which are routinely used to assess cross-reactivity. Here, we have used microfluidic antibody affinity profiling (MAAP) to quantitatively evaluate the humoral immune response in COVID-19 convalescent patients by determining both antibody affinity and concentration against spike antigens of SARS-CoV-2 directly in nine convalescent COVID-19 patient and three pre-pandemic sera that were seropositive for common HCoVs. All 12 sera contained low concentrations of high-affinity antibodies against spike antigens of HCoV-NL63 and HCoV-HKU1, indicative of past exposure to these pathogens, while the affinity against the SARS-CoV-2 spike protein was lower. These results suggest that cross-reactivity as a consequence of memory reactivation upon an acute SARS-CoV-2 infection may not be a significant factor in generating immunity against SARS-CoV-2. | |
dc.language | eng | |
dc.publisher | American Chemical Society (ACS) | |
dc.source | nlmid: 101654580 | |
dc.source | essn: 2373-8227 | |
dc.subject | Antibody affinity | |
dc.subject | cross-reactivity | |
dc.subject | Microfluidics | |
dc.subject | Antibody Profiling | |
dc.subject | Antibody Concentration | |
dc.subject | Sars-cov-2 | |
dc.subject | Humans | |
dc.subject | Antibodies, Viral | |
dc.subject | Antibody Affinity | |
dc.subject | Spike Glycoprotein, Coronavirus | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.title | Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2. | |
dc.type | Article | |
dc.date.updated | 2022-04-30T01:04:09Z | |
prism.endingPage | 799 | |
prism.issueIdentifier | 4 | |
prism.publicationName | ACS Infect Dis | |
prism.startingPage | 790 | |
prism.volume | 8 | |
dc.identifier.doi | 10.17863/CAM.84069 | |
rioxxterms.versionofrecord | 10.1021/acsinfecdis.1c00486 | |
rioxxterms.version | VoR | |
dc.contributor.orcid | Denninger, Viola [0000-0001-9770-8723] | |
dc.contributor.orcid | Xu, Catherine K [0000-0003-4726-636X] | |
dc.contributor.orcid | Meisl, Georg [0000-0002-6562-7715] | |
dc.contributor.orcid | Fiedler, Sebastian [0000-0003-0953-4327] | |
dc.contributor.orcid | Schneider, Matthias [0000-0002-1894-1859] | |
dc.contributor.orcid | Kosmoliaptsis, Vasilis [0000-0001-7298-1387] | |
dc.contributor.orcid | Knowles, Tuomas [0000-0002-7879-0140] | |
dc.identifier.eissn | 2373-8227 | |
pubs.funder-project-id | National Institute for Health Research (NIHR) (PD-2016-09-065) | |
pubs.funder-project-id | European Research Council (670958) | |
pubs.funder-project-id | Schweizerische Akademie der Medizinischen Wissenschaften (2017DRI17) | |
cam.issuedOnline | 2022-03-30 |
Files in this item
This item appears in the following Collection(s)
-
Jisc Publications Router
This collection holds Cambridge publications received from the Jisc Publications Router